All News
Filter News
Found 65,041 articles
-
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4/15/2024
BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.
-
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
4/15/2024
Aptevo Therapeutics Inc. (NASDAQ:APVO) today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common Warrant.
-
Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results
4/15/2024
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the second fiscal quarter ended February 29, 2024.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
U.S. Gene Therapy Market Size, Share & Growth Report, 2033
4/12/2024
According to Nova One Advisor, the U.S. gene therapy market size was valued at USD 3.19 billion in 2023
-
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused
4/12/2024
Portage Biotech Inc. today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
-
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4/12/2024
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent corporate activities.
-
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study
4/12/2024
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study
-
Orpyx to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4/12/2024
Orpyx, a med tech + touch company dedicated to transforming diabetic limb management, is pleased to announce that Dr. Breanne Everett, Founder and CEO
-
American Aires Announces Record Q4 and Annual 2023 Order Volume and Significant Q4 EBITDA Profitability
4/12/2024
American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) ("Aires" or the "Company"), a pioneer in cutting-edge technology designed to protect against electromagnetic
-
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
4/12/2024
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
-
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
4/12/2024
Compass Therapeutics, Inc. today announced poster presentations on CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024.
-
Biomerica Reports Third Quarter 2024 Financial Results
4/12/2024
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024.
-
Moderna Thursday said it paused plans to build an mRNA manufacturing facility in Kenya to buy time to assess vaccine demand after being hit with $1 billion in losses and write-downs due to canceled orders.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
4/11/2024
Baxter International Inc. announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. “These launches demonstrate Baxter’s focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter.
-
XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube
4/11/2024
SK Life Science, Inc. today announced the U.S. Food and Drug Administration (FDA) approved two new administration options of XCOPRI® (cenobamate tablets) CV, an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, which can now be crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.
-
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
4/11/2024
Tevogen Bio Holdings, is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
-
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
4/11/2024
Indaptus Therapeutics, Inc poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10th.